To the content
1 . 2021

The dynamics of carbohydrate metabolism associated with COVID-19 (role and place of Flash-glucose monitoring)

Abstract

These clinical cases show the reflection of the COVID-impact on the expression of different disturbance of carbohydrate metabolism, registrated using Flash glucose monitoring (hypo-, hyperglycemia, dynamics of glycemic variability). The first case presented the manifestation Diabetes Mellitus (DM) transformed from isolated 1-hr-postprandial hyperglycemia on the background of virus-associated в-cells disturbance at the intestinal COVID-variant. The second case generates interest due to confirmed stable course of Type 2 DM and metformin monotherapy at patients with COVID-19 and preexisted Type 2 DM/visceral obesity, postoperative disturbance of exocrine function of pancreas, who survived severe COVID-associated distress syndrome (cytokine storm demanded the usage of hydroxychloroquine and IL-6 blocker tolicizumab). Flash glucose monitoring allowed to detect and to correct high glycemic variability in the period of COVID-reconvalestation.

Keywords:type 2 diabetes mellitus, COVID-19, SARS-nCoV-2, glycemic variability, metformin, DPP4 inhibitors, flash glucose monitoring

Funding. The study had no sponsor support.

Conflict of interests. The authors declare no conflict of interests.

For citation: Ametov A.S., Kamynina L.L. The dynamics of carbohydrate metabolism associated with COVID-19 (role and place of Flash-glucose monitoring). Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2021; 10 (1): 78-87. DOI: https://doi.org/10.33029/2304-9529-2021-10-1-78-87 (in Russian)

References

1. Liu F., Long X., Zhang B., Zhang W., Chen X., Zhang Z. ACE 2 expression in pancreas may cause pancreatic damage after SARS-CoV-2 infection. Clin Gastroenterol Hepatol. 2020; 18 (9): 2128-30.e2. DOI: https://doi.org/10.1016/j.cgh.2020.04.040

2. Muniangi-Muhitu H., Akalestou E., Salem V., Misra S., Oliver N.S., Rutter G.A. COVID-19 and diabetes: a complex bidirectional relationship. Front Endocrinol (Lausanne). 2020; 11: 582936. DOI: https://doi.org/10.3389/fendo.2020.582936

3. Zhou Z., Sun B., Huang S., Zhu C., Bian M. Glycemic variability: adverse clinical outcomes and how to improve it? Cardiovasc Diabetol. 2020; 19: 102. DOI: https://doi.org/10.1186/s12933-020-01085-6

4. Danne T., Nimri R., Battelino T., Bergenstal R.M., Close K.L., DeVries J.H., et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017; 40 (12): 1631-40. DOI: https://doi.org/10.2337/dc17-1600

5. Battelino T., Danne T., Bergenstal R.M., Amiel S.A., Beck R., Biester T., et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019; 42 (8): 1593-603. DOI: https://doi.org/10.2337/dci19-0028

6. Ametov A.S., Kamynina L.L., Nazhmudinova P.K. Clinical aspects of the use of continuous glycemic monitoring in diabetology. Russkiy medit-sinskiy zhurnal [Russian Medical Journal]. 2013; 21 (28): 1401-4. (in Russian)

7 Chernikova N.A., Kamynina L.L., Ametov A.S. The cardiometabolic assessment of the glycemic variability in patients with diabetes mellitus: the role of the glucocardiomonitoring. Kardiologiya [Cardiology]. 2020; 60 (5): 100-6. DOI: https://doi.org/10.18087/cardio.2020.5.n902 (in Russian)

8. Bonora B.M., Boscari F., Avogaro A., Bruttomesso D., Fadini G.P. Gly-caemic control among people with type 1 diabetes during lockdown for the SARS-CoV-2 outbreak in Italy. Diabetes Ther. 2020; 11 (6): 1369-79. DOI: https://doi.org/10.1007/s13300-020-00829-7

9. Prabhu Navis J., Leelarathna L., Mubita W., et al. Impact of COVID-19 lockdown on flash and real-time glucose sensor users with type 1 diabetes in England. Acta Diabetol. 2020; 1-7 DOI: https://doi.org/10.1007/s00592-020-01614-5

10. Ametov A.S., Kamynina L.L. Contemporary interpretation of the oral glucose tolerance test with 75g glucose (diagnostic and prognostic approaches). Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2012; 1 (1): 45-9. (in Russian)

11. Dalan R., Bornstein S.R., El-Armouche A., Rodionov R.N., Markov A., Wie-lockx B., et al. The ACE-2 in COVID-19: foe or friend? Horm Metab Res. 2020; 52 (5): 257-63. DOI: https://doi.org/10.1055/a-1155-0501

12. Valencia I., Peiro C, Lorenzo 0., Sanchez-Ferrer C.F., Eckel J., Romacho T. DPP4 and ACE 2 in diabetes and COVID-19: therapeutic targets for cardiovascular complications? Front Pharmacol. 2020; 11: 1161. DOI: https://doi.org/10.3389/fphar.2020.01161

13. Samanta J., Gupta R., Singh M.P., Patnaik I., Kumar A., Kochhar R. Coro-navirus disease 2019 and the pancreas. Pancreatology. 2020; 20 (8): 1567-75. DOI: https://doi.org/10.1016/j.pan.2020.10.035

14. Caballero A.E., Ceriello A., Misra A., et al. COVID-19 in people living with diabetes: an international consensus. J Diabetes Complications. 2020; 34 (9): 107671. DOI: https://doi.org/10.1016/j.jdiacomp.2020.107671

15. Alessi J., de Oliveira G.B., Schaan B.D., Telo G.H. Dexamethasone in the era of COVID-19: friend or foe? An essay on the effects of dexamethasone and the potential risks of its inadvertent use in patients with diabetes. Diabetol Metab Syndr. 2020; 12: 80. DOI: https://doi.org/10.1186/s13098-020-00583-7

16. RECOVERY Collaborative Group; Horby P., Lim W.S., et al. Dexamethasone in hospitalized patients with COVID-19 - preliminary report. N Engl J Med. 2020; July 17 DOI: https://doi.org/10.1056/NEJMoa2021436

17 Scheen A.J. Metformin and COVID-19: From cellular mechanisms to reduced mortality. Diabetes Metab. 2020; 46 (6): 423-6. DOI: https://doi.org/10.1016/j.diabet.2020.07.006

18. Sharma S., Ray A., Sadasivam B. Metformin in COVID-19: a possible role beyond diabetes. Diabetes Res Clin Pract. 2020; 164: 108183. DOI: https://doi.org/10.1016/j.diabres.2020.108183

19. Bramante C., Ingraham N., Murray T., Marmor S., Hoversten S., Gronski J., et al. Observational study of metformin and risk of mortality in patients hospitalized with COVID-19. Version 2. medRxiv. 2020; Jun 28. DOI: https://doi.org/10.1101/2020.06.19.20135095

20. Yang J.K., Lin S.S., Ji X.J., Guo L.M. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010; 47 (3): 193-9. DOI: https://doi.org/10.1007/s00592-009-0109-4

21. Rubino F., Amiel S.A., Zimmet P., et al. New-onset diabetes in COVID-19. N Engl J Med. 2020; 383 (8): 789-90. DOI: https://doi.org/10.1056/NEJMc2018688

22. Alvarado-Vasquez N. Could a family history of type 2 diabetes be a risk factor to the endothelial damage in the patient with COVID-19? Med Hypotheses. 2020; 2020: 110378. DOI: https://doi.org/10.1016/j.mehy.2020.110378

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITOR
CHIEF EDITOR
Ametov Alexander S.
Honored Scientist of the Russian Federation, Doctor of Medical Sciences, Professor, Head of Subdepartment of Endocrinology, Head of the UNESCO Network Chair on the subject «Bioethics of diabetes as a global problem» of the Russian Medical Academy of Continuous Professional Education (Moscow)
Вскрытие

Journals of «GEOTAR-Media»